Endothelial Damage and Angiogenesis Biomarkers During COVID-19

University of Chile40 enrolled

Overview

Severe SARS-CoV-2 disease is characterized by a progressive hypoxemic respiratory failure. Autopsies from these patients show severe endothelial damage with extensive vascular thrombosis, microangiopathy, and occlusion of alveolar capillaries and, finally, evidence of new vessel growth through intussusceptive angiogenesis. This research aims to study endothelial damage and angiogenesis biomarkers and its association with major cardiovascular events.

To study the presence of endothelial damage and angiogenic biomarkers with major cardiovascular events, the investigators will perform an observational study to evaluate plasma biomarkers concentrations in Covid-19 patients hospitalized in critical care units. After ethical review board approval, the investigators will select 40 patients admitted to intensive care units (ICU). After patient written consent or if the participants are unable to consent, after a relative subrogated acceptance, the investigators will collect blood samples in the first 24 hrs and on the 10th day of hospitalization. Venous blood samples are collected. After obtaining all samples, serum Syndecan-1, thrombomodulin, ANG-2, FGF basic, HGF, IL-8, PDGF-BB, TIMP-1, TIMP-2, TNFα y VEGF will be determined by a researcher blinded to the patient using commercially available Elisa kits. The concentration of each biomarker at each sample time will be compared. The investigators will observe clinical outcomes after one, 3, 6, and 12 months after the hospitalization. The investigators found no previous data of this measurement in the COVID-19 scenario. In this observational study, the investigators select a sample size on convenience for the primary outcome.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Covid19 Angiogenesis Endothelial Dysfunction Cardiovascular Morbidity

Interventions

Endothelial damage and angiogenic biomarkersDIAGNOSTIC_TEST

Blood samples for biomarkers study

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients older than 18 years 2. Patient with a diagnosis of COVID-19 confirmed by PCR 3. Patient with radiological image suggestive of COVID-19 with pending confirmation 4. Need for ventilatory support with oxygen therapy by HFNC (High-flow nasal cannula) 5. Need for invasive mechanical ventilation. Exclusion Criteria: 1. Patient with an image suggestive of COVID-19 with negative PCR 2. Anticoagulation users before admission for any reason.

Locations (1)

Hospital Clínico de la Universidad de Chile

Independencia, Santiago Metropolitan, Chile

Outcomes

Primary Outcomes

Change from Baseline Syndecan-1 concentration at 10th day

Elevation of plasma Syndecan-1

Time frame: 24 Hours, 10 Days

Secondary Outcomes

Change from Baseline ANG-2 concentration at 10th day

Elevation of plasma ANG-2

Time frame: 24 Hours, 10 Days

Change from Baseline FGF basic concentration at 10th day

Elevation of plasma FGF basic

Time frame: 24 Hours, 10 Days

Change from Baseline HGF concentration at 10th day

Elevation of plasma HGF

Time frame: 24 Hours, 10 Days

Change from Baseline IL-8 concentration at 10th day

Elevation of plasma IL-8

Time frame: 24 Hours, 10 Days

Change from Baseline PDGF-BB concentration at 10th day

Elevation of plasma PDGF-BB

Time frame: 24 Hours, 10 Days

Change from Baseline TIMP-1 concentration at 10th day

Elevation of plasma TIMP-1

Time frame: 24 Hours, 10 Days

Change from Baseline TIMP-2 concentration at 10th day

Elevation of plasma TIMP-2

Time frame: 24 Hours, 10 Days

Change from Baseline TNFα concentration at 10th day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.